Search

Dry eye is multifactorial, yet some clinicians approach management of it one-dimensionally, relying solely on traditional treatments like artificial tears and prescription meds. Others have long stood beside the belief [...]

Adding an area of expertise can re-energize a practice by making it more profitable and avoiding burnout. These include myopia management, dry eye, neuro and retina--all lucrative and exciting opportunities [...]

There is no way to deny the potential impact of blue light, given the digital era we are in. To put this into perspective, there are approximately 340 million Americans, [...]

Although most clinicians consider dry eye and blepharitis as milder forms of ocular surface disease (OSD), they aren't to most patients, and masquerading conditions can be disfiguring or even life-threatening. [...]

As the clinical battle against the growing prevalence of dry eye continues, the industry has responded with new products and novel approaches to address this debilitating condition afflicting millions of [...]

Artificial intelligence is the current buzzword in all walks of life, but few know that it was first coined in 1956! It has taken time for technology to catch up [...]

Oncology has seen tremendous advancements in a few short years, including multiple FDA approvals in a rapidly expanding class of targeted therapies known as antibody-drug conjugates, or ADCs. These cancer-targeting [...]

The world of retina care continues to move at a rapid rate; staying on top of these advances can enhance our ability to practice fully, provide vision, prevent blindness and [...]

The world of dry eye disease (DED) is exploding, with an estimated 40 million Americans having the condition. (1) The good news--the recent release of new products into the market [...]

Let's dive into both worlds and explore new treatments. Corneal disease has always been a mainstay of optometry, and perhaps the reason we love it is that all the answers [...]

Untangling the Causes and Effects of DEMODEX BLEPHARITIS By Milton M. Horn, OD, FAAO; Paul M. Karpecki, OD, FAAO; and Ben Gaddie, OD First, there was dry eye, then it [...]

Demodex blepharitis is a significant public health challenge that rests largely on the shoulders of optometry. This condition is extremely prevalent and highly consequential in terms of patients' quality of [...]

Earn 2 CE Credits (COPE APPROVED) Presbyopia is front and center in most practices because it affects a wide age range of people, and patients are very vocal about their [...]

Every day, patients are referred for treatment of corneal-involved ocular surface diseases such as persistent epithelial defect (PED), recurrent corneal erosion (RCE), and epithelial basement membrane dystrophy (EBMD), among others. [...]

In all medical specialties, doctors have long relied on glucocorticoid therapy. However, it's well-known that systemic glucocorticoid treatments (e.g, oral prednisone) affect other cells in the body. In some patients, [...]

I recently took my daughter to urgent care for an upper respiratory infection and the doctor recommended OTC decongestants; I was miffed. I informed him that I had already tried [...]

The motivation for new diagnostic equipment has changed over the years. When I graduated, a well-known practice management consultant told me to determine how long it would take for reimbursement [...]

The new year is always an incredible opportunity to make a new start; to dream of the potential you want to achieve and then make it happen. The journey and [...]

Dear Colleagues, For many years, we in eye care had few reliable options to offer patients in the area of ocular redness relief due to minor eye irritation--commonly from conjunctival [...]

We are fortunate to have numerous interventions designed to address the ocular symptoms and local inflammatory component of chronic dry eye disease (DED), but treatment options for the neurological control [...]

Dry eye can be caused or exacerbated by many things, not the least of which is dehydration. Indeed, we have long been aware of the multifactorial nature of dry eye [...]

New meds and new laws give us unprecedented options. Dig in! I like the term surgical 'privileges, ' as it implies something you've earned, received and should maintain with pride [...]

Ocular surface disease (OSD) is right in front of us. Perhaps you have to express meibomian glands and have patients look down so you can scan their eyelids and instill [...]

During Reviews New Technologies & Treatments in Eye Care conference in Savannah, GA in August, I had the honor of providing a big-picture talk to the Intrepid Eye Society, which [...]

It's becoming clear that glaucoma patients are not compliant with topical medications if there is irritation upon instillation or the integrity of the ocular surface and vision is compromised. Here, [...]

It's been said, 'You can easily do any job as long as you have the right tool.' Optometrists may overlook valuable tools at their disposal to provide premium care to [...]

Correcting Presbyopia Using innovative IOL Technology Patient lifestyles and evolving technology are transforming the way we treat the growing population of presbyopic patients. Today's presbyopes live their lives differently than [...]

If we had addressed telemedicine back in March 2020, when we were forced to temporarily shut down our offices due to COVID, this would have been the number one topic [...]

We're in the early days of the rollout of Xdemvy (lotilaner ophthalmic solution 0.25% Tarsus), the first FDA-approved prescription medication for Demodex blepharitis, a condition that affects at least 25 [...]

The greatest ideas are often so simple that one's response is, 'Why didn't I think of that?' Simple doesn't mean lack of innovation, though. Just look at Post-it Notes and [...]

Although the market may be saturated with dry eye disease (DED) treatments, there is a new medication with the potential to separate itself from the rest. Last month the FDA [...]

With the recent approval of Syfovre (pegcetacoplan injection, Apellis Pharmaceuticals) for dry age-related macular degeneration (AMD)/geographic atrophy (GA), we have a great opportunity to lead and individualize patient management. Each [...]

Last month I talked about the new eyecare products available today, but there were too many to list in one column. Here, I'll discuss the rest of the lesser-known but [...]

It's hard to keep up with all the new eyecare products available today. This month, I'll point out some lesser-known innovations that help improve treatment outcomes and improve disease diagnosis. [...]

Over the past few months, three companies announced their second pivotal Phase III FDA trial results for novel ocular surface disease agents, and the results aren't just promising--they are exciting, [...]

Dry eye, as we understand it today, is entirely different than it was 20--or even 10--years ago. Of course, the disease itself has not changed, but our understanding of it [...]